What are the key learnings from the 7-year follow-up of PARTNER 3?

Listen to this PCR London Valves 2025 interview with Philippe Généreux and Philippe Pibarot, who explore the 7-year results of PARTNER 3 in low-risk patients.They walk through the main findings of this TAVR versus SAVR comparison in symptomatic severe aortic stenosis (AS). At 7 years, the primary endpoint — the composite of mortality, stroke and rehospitalisation — shows similar rates between both strategies.The conversation then turns to valve durability and whether the early promises of TAVR are being fulfilled when compared with surgery, what still needs to be improved on each side, and how these long-term data might influence clinical practice now that two strong options exist for low-risk patients.They conclude by highlighting how Heart Team discussions will become even more crucial in this context.Curious to learn more? Hit play! Hosted on Acast. See acast.com/privacy for more information.